Interleukin-10 (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Interleukin-10" in German language version.

refsWebsite

Global rank German rank

5doi.org

2^nd place

3^rd place

4nih.gov

4^th place

7^th place

1ebi.ac.uk

5,849^th place

4,709^th place

doi.org

Gerald Grütz: New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. In: Journal of Leukocyte Biology. Band 77, Nr. 1, Januar 2005, S. 3–15, doi:10.1189/jlb.0904484, PMID 15522916.
J. Randolph Hecht, Sara Lonardi, Johanna Bendell, Hao-Wen Sim, Teresa Macarulla: Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). In: Journal of Clinical Oncology. Band 39, Nr. 10, 1. April 2021, S. 1108–1118, doi:10.1200/JCO.20.02232, PMID 33555926, PMC 8078437 (freier Volltext).
John B. Mumm, Jan Emmerich, Xueqing Zhang, Ivan Chan, Lingling Wu: IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance. In: Cancer Cell. Band 20, Nr. 6, Dezember 2011, S. 781–796, doi:10.1016/j.ccr.2011.11.003.
Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Manish R. Patel: Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. In: Journal of Clinical Oncology. Band 34, Nr. 29, 10. Oktober 2016, S. 3562–3569, doi:10.1200/JCO.2016.68.1106, PMID 27528724, PMC 5657013 (freier Volltext).
Aung Naing, Deborah J. Wong, Jeffrey R. Infante, W. Michael Korn, Raid Aljumaily: Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. In: The Lancet. Oncology. Band 20, Nr. 11, November 2019, S. 1544–1555, doi:10.1016/S1470-2045(19)30514-5, PMID 31563517, PMC 8436252 (freier Volltext).

ebi.ac.uk

InterPro: IPR000098 Interleukin-10 (englisch)

nih.gov

ncbi.nlm.nih.gov

Gerald Grütz: New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. In: Journal of Leukocyte Biology. Band 77, Nr. 1, Januar 2005, S. 3–15, doi:10.1189/jlb.0904484, PMID 15522916.
J. Randolph Hecht, Sara Lonardi, Johanna Bendell, Hao-Wen Sim, Teresa Macarulla: Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). In: Journal of Clinical Oncology. Band 39, Nr. 10, 1. April 2021, S. 1108–1118, doi:10.1200/JCO.20.02232, PMID 33555926, PMC 8078437 (freier Volltext).
Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Manish R. Patel: Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. In: Journal of Clinical Oncology. Band 34, Nr. 29, 10. Oktober 2016, S. 3562–3569, doi:10.1200/JCO.2016.68.1106, PMID 27528724, PMC 5657013 (freier Volltext).
Aung Naing, Deborah J. Wong, Jeffrey R. Infante, W. Michael Korn, Raid Aljumaily: Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. In: The Lancet. Oncology. Band 20, Nr. 11, November 2019, S. 1544–1555, doi:10.1016/S1470-2045(19)30514-5, PMID 31563517, PMC 8436252 (freier Volltext).